Adipotide is a research-only compound tested only in animals. There is no established human dose, and animal studies showed kidney toxicity. Any numbers seen online are not medically established. This page is education, not a protocol, and describes no usable regimen.
Overview
Adipotide (also called FTPP) is a designed peptidomimetic: a targeting sequence paired with a pro-apoptotic element, intended to home to the blood supply of white fat and trigger local cell death. Its effects are known almost entirely from rodent and primate studies.
What is known about dosing
There is no common human dosing pattern to report:
- Adipotide has never been established in approved human use; published work is preclinical (animal) research.
- Amounts used in animal studies are specific to those experiments and species and do not translate to a human dose.
- Animal studies reported renal (kidney) toxicity, a serious dose-limiting problem.
Because the safety margin observed in animals was narrow, no informal number could be considered safe.
Why no dose can be given
Providing a figure would falsely imply a validated, safe amount exists. It does not. The compound never advanced to established human use, and its most notable finding was organ toxicity. Responsible education means stating clearly that no established dose exists and none should be inferred from animal data.
Why oversight matters
Adipotide is designed to kill cells in targeted tissue, and imperfect selectivity is exactly what drives its toxicity. Any legitimate investigation would occur only within a controlled research setting with intensive monitoring, particularly of kidney function. This is not a compound with a self-administered protocol.
For a broader overview, see the main adipotide reference page and the safety-focused guide.